_256_384.jpg)
In FY21, the company reported a net profit of Rs 419 crores compared to Rs 101 crores in FY 20 and consolidated total income at Rs 6092 crores, up 19% Y-o-Y
The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
The financing secures funds to advance the clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
The group has a total of 320 ANDA approvals
It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
The company has tied up with OrbiMed as a financial partner for global reach
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
